Group One Trading
ESPR

Group One Trading’s Esperion Therapeutics ESPR Stock Holding History

Group One Trading’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Sell
101,700
-497,900
-83% -$1.39M ﹤0.01% 3898
2026
Q1 		$1.64M Sell
599,600
-396,400
-40% -$1.25M ﹤0.01% 2248
2025
Q4 		$3.69M Buy
996,000
+634,100
+175% +$2.05M 0.01% 1763
2025
Q3 		$959K Buy
361,900
+311,000
+611% +$602K ﹤0.01% 3076
2025
Q2 		$50.1K Sell
50,900
-51,200
-50% -$51.3K ﹤0.01% 5573
2025
Q1 		$147K Sell
102,100
-244,300
-71% -$450K ﹤0.01% 4269
2024
Q4 		$762K Buy
346,400
+169,500
+96% +$395K ﹤0.01% 2811
2024
Q3 		$292K Sell
176,900
-100,700
-36% -$203K ﹤0.01% 3287
2024
Q2 		$616K Sell
277,600
-115,600
-29% -$272K ﹤0.01% 2374
2024
Q1 		$1.05M Sell
393,200
-211,700
-35% -$514K ﹤0.01% 2036
2023
Q4 		$1.81M Buy
604,900
+349,100
+136% +$453K ﹤0.01% 1957
2023
Q3 		$251K Buy
255,800
+69,800
+38% +$101K ﹤0.01% 3609
2023
Q2 		$259K Sell
186,000
-240,400
-56% -$336K ﹤0.01% 3673
2023
Q1 		$678K Sell
426,400
-367,600
-46% -$1.9M ﹤0.01% 2479
2022
Q4 		$4.95M Buy
794,000
+73,800
+10% +$528K 0.01% 1154
2022
Q3 		$4.83M Buy
720,200
+10,700
+2% +$73.5K 0.01% 1188
2022
Q2 		$4.51M Buy
709,500
+216,600
+44% +$1.23M 0.01% 1373
2022
Q1 		$2.29M Buy
492,900
+26,400
+6% +$113K ﹤0.01% 2269
2021
Q4 		$2.33M Buy
466,500
+390,500
+514% +$3.13M ﹤0.01% 2430
2021
Q3 		$916K Buy
76,000
+26,900
+55% +$392K ﹤0.01% 3513
2021
Q2 		$1.04M Sell
49,100
-29,800
-38% -$718K ﹤0.01% 3371
2021
Q1 		$2.21M Buy
78,900
+18,400
+30% +$543K ﹤0.01% 2362
2020
Q4 		$1.57M Buy
60,500
+26,600
+78% +$797K ﹤0.01% 2247
2020
Q3 		$1.26M Buy
33,900
+4,100
+14% +$162K ﹤0.01% 1988
2020
Q2 		$1.53M Sell
29,800
-12,900
-30% -$540K 0.01% 1666
2020
Q1 		$1.35M Buy
42,700
+14,000
+49% +$739K 0.01% 1302
2019
Q4 		$1.71M Buy
28,700
+16,500
+135% +$742K 0.01% 1416
2019
Q3 		$447K Buy
12,200
+5,000
+69% +$198K ﹤0.01% 2426
2019
Q2 		$335K Buy
7,200
+1,000
+16% +$47K ﹤0.01% 2495
2019
Q1 		$249K Sell
6,200
-59,800
-91% -$2.68M ﹤0.01% 2541
2018
Q4 		$3.04M Buy
66,000
+41,000
+164% +$1.98M 0.03% 765
2018
Q3 		$1.11M Buy
25,000
+1,100
+5% +$50.5K 0.01% 1625
2018
Q2 		$937K Sell
23,900
-43,700
-65% -$2.21M 0.01% 1785
2018
Q1 		$4.89M Buy
67,600
+46,800
+225% +$3.44M 0.05% 487
2017
Q4 		$1.37M Sell
20,800
-200
-1% -$10.8K 0.01% 1456
2017
Q3 		$1.05M Sell
21,000
-35,600
-63% -$1.72M 0.01% 1527
2017
Q2 		$2.62M Buy
56,600
+33,900
+149% +$1.25M 0.03% 795
2017
Q1 		$802K Buy
22,700
+22,600
+22,600% +$518K 0.01% 1494
2016
Q4 		$1K Sell
100
-63,200
-100% -$753K ﹤0.01% 4305
2016
Q3 		$877K Buy
63,300
+61,700
+3,856% +$699K 0.01% 1366
2016
Q2 		$16K Buy
1,600
+1,500
+1,500% +$24.9K ﹤0.01% 3891
2016
Q1 		$2K Sell
100
-29,400
-100% -$473K ﹤0.01% 4366
2015
Q4 		$657K Sell
29,500
-60,400
-67% -$1.52M 0.01% 1601
2015
Q3 		$2.12M Buy
89,900
+53,900
+150% +$3.38M 0.03% 747
2015
Q2 		$2.94M Buy
36,000
+26,000
+260% +$2.55M 0.04% 543
2015
Q1 		$926K Buy
10,000
+700
+8% +$45.2K 0.01% 1144
2014
Q4 		$376K Buy
+9,300
New +$285K 0.01% 1781

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Group One Trading's ESPR Position: Q2 2026 in Review

Group One Trading opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 242,645 shares worth $767K. The stake represents ﹤0.01% of the portfolio and ranks #3133 among its holdings. This is a return to the name: Group One Trading previously reported a position in ESPR as recently as Q3 2025.

Group One Trading first reported a position in ESPR in Q4 2014 and has held it in 30 quarters since. The position peaked at $2.06M in Q1 2017. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Group One Trading held 242,645 shares of Esperion Therapeutics worth $767K as of Q2 2026.
  • Esperion Therapeutics was a new Group One Trading position in Q2 2026.
  • Esperion Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #3133 holding.
  • Group One Trading first reported a position in Esperion Therapeutics in Q4 2014 and has held it in 30 quarters since.
  • Group One Trading's Esperion Therapeutics position peaked at $2.06M in Q1 2017.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.